Conclusions Based on our initial data, we conclude that the Trevo NXT is an effective and safe tool for mechanical thrombectomy especially when used for combined approaches.
Disclosure Nothing to disclose

EP53* **THE NOVEL TENZING INSERTS – THE SEAMLESS WAY TO REACH THE CLOT IN LARGE AND MIDDLE VESSEL CEREBRAL OCCLUSIONS – PRELIMINARY EXPERIENCE**

F Massari, J Singh, AL Kuhn, V Naragum, V Anagnostakou, MJ Gounis, AS Puri. *University of Massachusetts, Worcester, MA, USA*

10.1136/neurintsurg-2021-ESMINT.52

Introduction-Objectives To report the feasibility, safety and efficacy in utilizing the novel Tenzing inserts during stroke thrombectomy in order to reach the clot with large bore catheters, without need for crossing.

Aims-Methods The distal trackability of the new generation of super large bore aspiration catheters is provided by the newly engineered Tenzing inserts, which present virtually atraumatic self-centering soft tapered tip, capable to navigate the tortuous cervico-cranial vasculature with very unfrequently necessity of an inner microwire, the extremely large shaft which almost zeroes the step-off with the aspiration catheters, reducing the risk to get stuck at the level of vascular ledges/bifurcations and the unnecessary to cross the embolus, which significantly reduce the risk of downstream clot embolization. The Tenzing 7 is compatible with large bore aspiration catheters, while the Tenzing 8 matches the 088' HiPoint super large bore catheter, which in combination with the Base Camp guiding catheter is utilized for the Mount Everest Technique (MET).

Results We have utilized this novel insert in 20 patients with large and moderate vessel occlusions involving the anterior (19; 8 ICA, 8 MCA-M1, 3 MCA-M2) and posterior¹ circulation with 100% efficacy. No embolization in unaffected vascular territories or symptomatic SAH has been observed.

Conclusions In our preliminary experience, the utilization of the novel Tenzing inserts proved to be extremely effective in reaching the clot with large and super large bore catheters, without the necessity to cross the embolus as well as without encountering the issue of getting stuck at the level of vascular ledges/bifurcations.

REFERENCE

1. Frölich AM, Kim W, Stribny K, Jansen O, Möhlenbruch M, Szikora I, Wodarg F, Fiehler J, Otto K, Chou T, Buhk JH, English J. The novel Tenzing 7 delivery catheter designed to deliver intermediate catheters to the face of embolus without crossing: clinical performance predicted in anatomically challenging model. *J Neurointerv Surg* 2020 Sep 3;neurintsurg-2020-016412.

Disclosure Nothing to disclose

EP54* **UTILITY OF DRUG-ELUTING COROFLEX ISAR STENT IN INTRACRANIAL ATHEROSCLEROTIC DISEASE: A SINGLE CENTER EXPERIENCE IN 147 PATIENTS**

A El Mekabaty, V Hellstern, M Auguilar-Perez, H Henkes. *Diagnostic and Interventional Neuroradiology, Klinikum Stuttgart Katharienenhospital, Stuttgart, Germany*

10.1136/neurintsurg-2021-ESMINT.53

Introduction Intracranial atherosclerotic disease (ICAD) is a major cause of stroke worldwide. Different treatment regimen,

including medical treatment (e.g. dual antiplatelet inhibition) and endovascular treatment are available. We aim to investigate the safety and efficacy of the drug-eluting, balloon-mounted Coroflex ISAR stent in patients with ICAD.

Methods A retrospective analysis of patients with ICAD and attempted implantation of Coroflex ISAR stent in our institution from 2014 to 2020 was performed.

Results A total of 147 patients were included (74.1% males, average age 70 years 'range 47–93'). Median baseline modified Rankin score (mRS) was 0 (interquartile range 'IQR' 0–1) and median pretreatment mRS was 2 (IQR 1–4). Lesions treated were located in the ICA (42.9%), V4 segment (36.1%), basilar artery (12.2%) and M1 segment (8.8%). Stent was successfully implanted in 92.6% (137/147) and the vessel stenosis was reduced from a mean of 76% 'range 50–99' to 36% 'range 0–82'. Short-term follow-up was available in 77.7% of patients after a median of 3 months 'IQR 1–5' and long-term follow-up was available in 63.3% (93/147) after a median of 24 months 'IQR 14–40'. In-Stent stenosis occurred in 13.9% (16/115), recurrent stroke in 9.5% (11/115) and asymptomatic intracranial hemorrhage in 3.4% (5/147). Over-all mortality was 4.1% (6/147).

Conclusion The drug-eluting, balloon-mounted Coroflex ISAR is a safe and effective treatment option for ICAD. The overall recurrent stroke rate was 9.5% and mortality was 4.1%. Further work is needed to better identify ICAD patients for stenting.

REFERENCES

1. Ye G, et al. Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease: a systematic review and meta-analysis. *J Clin Neurosci* 2019 Jan;59:112–118.
2. Vajda Z, et al. Treatment of intracranial atherosclerotic disease with a balloon-expandable paclitaxel eluting stent: procedural safety, efficacy and mid-term patency. *Clin Neuroradiol* 2012 Sep;22(3):227–33.

Disclosure Nothing to disclose

EP55 **KEEP IT SIMPLE: THE SNACE (SOFIA NON-WIRE ASPIRATION CONTRAST ENHANCEMENT) TECHNIQUE FOR THE ENDOVASCULAR MANAGEMENT OF ACUTE ISCHEMIC STROKE**

B Pabon, V Torres, J Mejia, M Patiño, O Vargas, N Serna, J Pelaez. *Angioteam, Medellín, Colombia*

10.1136/neurintsurg-2021-ESMINT.54

Background The availability of advanced large-bore diameter aspiration catheters has improved recanalization rates and time. We report a prospectively collected clinical experience with a simple technique: SNACE (Sofia Non-wire Aspiration Contrast Enhancement) as the primary method for vessel recanalization.

Methods 38 prospective patients with ELVO at four institutions were included in the study. The SNACE technique was utilized in all patients. Procedural and clinical data were analyzed.

Results The SNACE approach using SOFIA 6 Plus Catheter was successful in achieving Thrombolysis in Cerebral Infarction (TICI) 2b or 3 revascularizations in 88% of cases. The first Pass effect was obtained in 75%. The average time from groin puncture to at least TICI 2b recanalization was 17 min. National Institutes of Health Stroke Scale (NIHSS) score average at the onset of 16 and improved to a median NIHSS